STD PREVENTION-PRIMATE UNIT

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 性传播疾病预防灵长类单位(STDP-PU)合同已经建立，作为一种手段，比较评估外用杀微生物剂产品在重复使用后对宫颈/阴道组织的安全性，以及在预防宫颈衣原体感染方面的有效性。 该合同旨在首先评估配方杀微生物剂产品对宫颈和阴道表面组织和微环境(改良阴道镜、宫颈革兰氏染色、PH值、阴道菌群)的影响，包括每天使用30分钟和24小时后连续使用4天。这项实验测试了最后使用后一周内组织和菌群的恢复情况。 在一种产品被证明在重复使用后不会导致有害结果后，将对其预防宫颈衣原体感染的能力进行评估。在这个实验中，将单剂量的配方杀微生物剂产品应用于六只动物中的每一只，然后(在30分钟内)对沙眼衣原体进行颈部攻击。在接种后的七周内，将尝试检测活的衣原体生物体和DNA，以及血清衣原体抗体。 这项合同已扩大到包括进行疗效研究、评估预防滴虫感染以及衣原体研究的可能性。 这份NIH合同于2008年4月30日结束。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The Sexually Transmitted Disease PreventionPrimate Unit (STDP-PU) contract has been established as a means to comparatively assess topical microbicide products vis-¿-vis safety to cervical/vaginal tissues after repeated use, and efficacy in preventing cervical chlamydial infection. The contract is designed to assess first, effects that a formulated microbicide product has on the surface tissues and microenvironment of the cervix and vagina (modified colposcopy, cervical gram stain, pH, vaginal flora), thirty minutes and 24 hours after each application when applied daily for four days. This experiment tests for tissue and flora recovery within one week following final application. After a product has been shown not to induce deleterious outcome after repeated use, it will be assessed for its ability to prevent chlamydial infection of the cervix. In this experiment, a single dose of the formulated microbicide product is applied to each of six animals, followed (at thirty minutes) by a cervical challenge with Chlamydia trachomatis. Detection of viable chlamydial organisms and DNA, as well as serum antibody to chlamydia will be attempted for seven weeks post inoculation. This contract has been expanded to include the potential for conducting efficacy studies assessing prevention of Trichomonas vaginalis infection as well as chlamydia studies. This NIH contract closed 4-30-2008.